Summit Therapeutics

AstraZeneca

#ASCO25 tracker: Meeting kicks off in Chicago with high expectations in breast, lung cancer

Merck

Keytruda

lung cancer

BioSpace

Fri, 05/30/25 - 11:49 am

Summit’s bispecific misses survival endpoint in global phase III trial but analysts remain optimistic

BioSpace

Fri, 05/30/25 - 11:46 am

With new trial win, Akeso bispecific shows prior success against Keytruda is no 'fluke'

Fierce Pharma

Thu, 04/24/25 - 10:53 am

Akeso Biopharma

bispecific antibodies

lung cancer

clinical trials

This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year

Motley Fool

Thu, 03/13/25 - 11:32 am

cancer

Pfizer inks deal to test Summit’s white-hot bispecific with ADCs

Fierce Biotech

Mon, 02/24/25 - 11:11 am

Pfizer

Ivonescimab Looking to Rival Merck’s Keytruda in NSCLC with Phase III Trial Enrollment Complete

antibody-drug conjugates

BioNTech to buy Biotheus, gaining control of cancer bispecific

BioPharma Dive

Wed, 11/13/24 - 11:30 am

Xtalks

Thu, 10/10/24 - 10:02 am

clinical trials

Merck

Keytruda

Keytruda beaten by Summit’s bispecific in NSCLC

Clinical Trials Arena

Fri, 09/20/24 - 11:15 am

Summit lung cancer drug shows ‘striking’ benefit over Keytruda

BioPharma Dive

Sun, 09/8/24 - 11:32 pm

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

BioSpace

Mon, 06/3/24 - 12:02 pm

Summit makes case for changes to antibiotic R&D after sharing data from failed phase 3 trial

funding

Fierce Biotech

Fri, 10/21/22 - 10:59 am

Summit will take scenic route up FDA mountain after regulator recommends more trials for C. diff therapy

Fierce Biotech

Thu, 07/14/22 - 07:51 pm

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial

ridinilazole

C. difficile

Summit says path forward for failed C. difficile drug is likely through partnerships

Fierce Biotech

Sun, 03/20/22 - 10:52 pm

CP Wire

Fri, 08/3/18 - 11:04 am

C. difficile

microbiome ridinilazole

Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure

Xconomy

Wed, 06/27/18 - 11:56 am

ezutromid

clinical trials

Data from trials could send these clinical-stage biotech stocks soaring or crashing

Motley Fool

Mon, 02/5/18 - 08:26 am

How the newest Duchenne biotechs are getting a boost from patient groups

Bizjournals.com

Mon, 02/27/17 - 09:15 am

patients

patient groups

Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug

Yahoo/Benzinga

Tue, 10/4/16 - 03:58 pm

Sarepta Therapeutics

Europe

ezutromid

Sarepta: The Competition Is At The Gate

Seeking Alpha

Fri, 08/12/16 - 09:53 am